Could ecstasy help treat bulimia? early trial begins

NCT ID NCT07542145

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests whether MDMA (the active ingredient in ecstasy) combined with talk therapy can help people with bulimia nervosa. Forty adults will be assigned to one of three groups: MDMA with general therapy, MDMA with bulimia-specific therapy, or standard treatment alone. The goal is to see if the drug helps reduce binge eating episodes by making therapy more effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MDMA (also known as ecstasy or molly)
What this could lead to
If it works, this could point toward a new treatment option for bulimia nervosa that combines therapy with a drug to reduce fear and increase openness.
What could go wrong
This is a very early Phase 1 trial with only 40 people, so results may not apply widely. MDMA can cause side effects like increased heart rate, anxiety, or confusion, and the therapy is intensive and not yet proven effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BULIMIA NERVOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

binge eating disorder bulimia nervosa Feeding and Eating Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Psychiatry, Eating and Weight Disorders Program

    RECRUITING

    New York, New York, 10028, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.